Vol.123 2024 Taiwan Biotech & Pharma: A Year in Review
Model: Vol.123
Category: Media & Other Services
Exhibitor: GLOBAL BIO & INVESTMENT MONTHLY
Booth No: N631
Characteristic
Taiwan Biotech in 2024: A Powerful Closing Surge
This year marked impressive momentum—36 new listings, 16 drug approvals, and 12 successful clinical milestones.
What strategic moves are set for 2025? Discover where the next wave of biotech breakthroughs is taking shape.
Other Products
Products you may be interested in
Highest Rated Products